Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Melanoma | Pharmaceuticals | Skin Cancer